These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30848211)

  • 1. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.
    Scotto R; Buonomo AR; Moriello NS; Maraolo AE; Zappulo E; Pinchera B; Gentile I; Borgia G
    Rev Recent Clin Trials; 2019; 14(3):173-182. PubMed ID: 30848211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
    Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
    Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
    Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    Vermehren J; Park JS; Jacobson IM; Zeuzem S
    J Hepatol; 2018 Nov; 69(5):1178-1187. PubMed ID: 30006068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
    Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
    J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center.
    El Kassas M; Eltabbakh M; Elbadry M; Tawheed A; Elbaz T
    Curr Med Res Opin; 2022 Apr; 38(4):553-563. PubMed ID: 35118916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
    Weisberg IS; Jacobson IM
    Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
    Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
    Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
    J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
    Mettikanont P; Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Jackson WE; Everson GT
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.